Similar Items: Population pharmacokinetic modelling to address the gaps in knowledge of commonly used HIV and TB drugs in children
- Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacogenomics and pharmacokinetics of antiretroviral drugs and their associations with metabolic complications in HIV-infected Black South Africans
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
Author: Denti, Paolo
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- A scoping review on the use of telerehabilitation in physiotherapy in low and middle income countries
- Advancing tuberculosis treatment through pharmacometric modeling of drug exposure and biomarkers